Usha Niranjan
Medical Oncology · Hackettstown, NJNPI 1396733077
Payments from drug & device makers
Across 59 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$123
- Novartis$91
- Daiichi Sankyo Inc.$78
- Merck$77
- Bayer$65
- Amgen$61
- plus $509 from 19 others
What the payments were for
- Food & beverage$99399%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $123 |
| Novartis | 4 | $91 |
| Daiichi Sankyo Inc. | 4 | $78 |
| Merck | 5 | $77 |
| Bayer | 4 | $65 |
| Amgen | 4 | $61 |
| Pfizer | 4 | $60 |
| Boehringer Ingelheim | 2 | $43 |
| Genentech USA, Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Lilly USA, LLC | 2 | $37 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $29 |
| Incyte Corporation | 2 | $29 |
| Sanofi | 2 | $29 |
| Mirati Therapeutics, Inc. | 1 | $26 |
| Sobi, Inc | 1 | $25 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| Astellas Pharma US Inc | 1 | $22 |
| AbbVie | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$1,004 in reported general payments places this provider in the 30th percentile of 112 medical oncology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 13 | $256,159 |
| EliquisApixaban | 37 | $32,249 |
| XareltoRivaroxaban | 15 | $17,855 |
| Hydroxyurea | 29 | $656 |
| Anastrozole | 24 | $453 |
| Acyclovir | 24 | $280 |
| Warfarin Sodium | 29 | $182 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $100 |
| JantovenWarfarin Sodium | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $40 | $256,15913 claims |
| PfizerEliquis | $60 | $32,24937 claims |
| Johnson & JohnsonXarelto | $15 | $17,85515 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $13 | $28024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Hackettstown
- Martin GutierrezHackensack$41.8M
- James McCloskeyHackensack$17.1M
- Lori LeslieHackensack$11.9M
- Tatyana FeldmanHackensack$8.4M
- Benjamin FreemanMorristown$7.5M
- Kristen SpencerNew Brunswick$7.2M
- David SiegelHackensack$6.9M
- Biren SaraiyaNew Brunswick$6.2M
- Noa BiranHackensack$5.8M
- Sanjay GoelNew Brunswick$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.